Results 11 to 20 of about 4,011 (178)
Pulmonary Circulation, 2021 Oral treprostinil has recently been shown to delay disease progression in patients with pulmonary arterial hypertension in a long-term outcomes study. The potential advantages of an oral formulation have resulted in patients transitioning from inhaled to
Diane L. Zwicke +7 more
doaj +2 more sources
Cells, 2023 (1) Pulmonary hypertension (PH)-associated right ventricular (RV) failure is linked to a reduction in pulmonary vasodilators. Treprostinil has shown effectiveness in PAH patients with cardiac decompensation, hinting at potential cardiac benefits.
Aleksandra Judina +8 more
doaj +2 more sources
The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels [PDF]
Frontiers in Pharmacology, 2021 Pulmonary arterial hypertension (PAH) is an aggressive vascular remodeling disease that carries a high morbidity and mortality rate. Treprostinil (Remodulin) is a stable prostacyclin analogue with potent vasodilatory and anti-proliferative activity ...
Kevin P. Cunningham +5 more
doaj +2 more sources
The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, 2011 Inhaled treprostinil is a safe and well-tolerated approved pharmaceutical for the treatment of pulmonary arterial hypertension. In a series of open-label studies and in the pivotal trial with 253 patients, this long-acting prostacyclin analogue ...
Tobias Gessler +2 more
doaj +3 more sources
Scientific Reports, 2018 Idiopathic pulmonary fibrosis (IPF) is characterized by peripheral lung fibrosis and increased interstitial extracellular matrix (ECM) deposition. In IPF, tumor growth factor (TGF)-β1 which is the major stimulus of ECM deposition, and platelet derived ...
Christopher Lambers +7 more
doaj +2 more sources
Pulmonary CirculationIn patients with pulmonary arterial hypertension (PAH), limited real‐world data are available on persistence to oral treprostinil therapy, particularly while transitioning from parenteral prostacyclins.
Daniel J. Lachant +6 more
doaj +2 more sources
Inhaled treprostinil: a therapeutic review
Drug Design, Development and Therapy, 2012 Richard N Channick1, Robert Voswinckel2,3, Lewis J Rubin41Pulmonary Hypertension Program, Massachusetts General Hospital, Boston, MA, USA; 2University of Giessen Lung Center, Dept.
Channick RN, Voswinckel R, Rubin LJ
doaj +1 more source
BMC Pulmonary Medicine, 2017 Background In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise ...
Asuka Furukawa +6 more
doaj +2 more sources
Experiences with treprostinil in the treatment of pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, 2012 Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the ...
Amanda R. Stream, Todd M. Bull
doaj +2 more sources
, 2018 Treprostinil diolamine is the first oral dosage preparation of a prostacyclin analogue for use in treatment naive pulmonary arterial hypertension (PAH). This case series and review of the available literature describes the experience of patients with PAH
Smith, Zachary R +3 more
core +5 more sources